비강 스프레이 시장 : 유형별, 용도별, 환자별, 유통 채널별 - 세계 예측(2023-2032년)

Nasal Spray Market is anticipated to experience robust growth during the forecast timeline from 2023 to 2032 due to the increasing prevalence of allergic rhinitis and sinusitis.

With rising environmental pollutants and changing lifestyles, more individuals are afflicted by these respiratory conditions, driving up demand for nasal sprays. According to the World Allergy Organization, more than 400 million individuals worldwide suffer from allergic rhinitis, which is often misdiagnosed and undertreated. It affects 10-30% of the adult general population and up to 40% of children in the United States, making it the sixth most prevalent chronic condition. Nasal sprays provide instant relief from congestion and related symptoms, offering a convenient solution for sufferers.

Moreover, pharmaceutical companies are actively developing innovative formulations to cater to this growing demand, further propelling the market growth. To cite an instance, in May 2023, Bausch Health Companies Inc. announced the launch of RYALTRIS®, a novel prescription therapy authorized by Health Canada for the symptomatic management of moderate mild to severe seasonal allergic rhinitis and associated symptoms in children, adolescents, and adults.

The nasal spray market is classified by type, application, patient, distribution channel, and region.

The antihistamine nasal spray market accounted for a substantial revenue share and is estimated to gain notable traction through 2032, attributed to their widespread use in the treatment of allergic rhinitis. These sprays work by blocking histamine receptors, alleviating allergy symptoms effectively. As patients seek rapid and long-lasting solutions, pharmaceutical companies continue developing and marketing antihistamine nasal sprays, contributing to the segment growth. For instance, In June 2022, Astepro allergy nasal spray from Bayer received FDA clearance for over-the-counter use. It is the very first steroid-free antihistamine nasal spray for the treatment of allergies to be approved for over-the-counter usage in the USA.

The nasal spray market share from the allergic rhinitis application segment is poised to amass considerable revenue share by the end of 2032. With the rising incidence of allergic rhinitis worldwide, there has been a corresponding surge in demand for nasal sprays as a primary mode of treatment. The preference for nasal sprays is rising due to their convenience and non-invasiveness in the management of allergic rhinitis, which will positively impact the segment growth.

Based on the distribution channel, the nasal spray market from the hospital segment could grow at a robust growth rate from 2023-2032, driven by the constant influx of patients seeking treatment for various medical conditions. Additionally, many nasal sprays are prescription-based, and hospitals are well-equipped to issue prescriptions and dispense these products directly to patients. This inherent capability ensures a reliable and efficient supply chain for nasal sprays, offering patients seamless access to the required medications, further bolstering the segment revenue through 2032.

The Asia Pacific nasal spray industry will expand significantly through 2032, driven by the increasing awareness of nasal sprays as a convenient and effective remedy for respiratory conditions. Additionally, the rapidly growing population in APAC, in line with the aging demographic, has increased the prevalence of chronic ailments that often require nasal sprays. Furthermore, the presence of improved healthcare infrastructure, access to healthcare information, and rising disposable income in many APAC countries have made nasal sprays more accessible and affordable, thereby driving market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market definitions
• 1.2 Base estimates and calculations
• 1.3 Forecast calculations
• 1.4 Data sources
  • 1.4.1 Secondary
    • 1.4.1.1 Paid sources
    • 1.4.1.2 Public sources
  • 1.4.2 Primary

Chapter 2 Executive Summary

• 2.1 Nasal spray industry 360 degree synopsis, 2018 - 2032 (USD Billion)
  • 2.1.1 Business trends
  • 2.1.2 Type trends
  • 2.1.3 Application trends
  • 2.1.4 Patient type trends
  • 2.1.5 Distribution channel trends
  • 2.1.6 Region trends

Chapter 3 Nasal Spray Market Insights

• 3.1 Industry landscape, 2018 - 2032 (USD Billion)
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increase in prevalence of chronic respiratory diseases and nasal disorders
    • 3.2.1.2 Increasing number of nasal spray product development and launches
    • 3.2.1.3 Rise in demand for nasal sprays
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects associated with nasal sprays
• 3.3 Growth potential analysis
  • 3.3.1 By type
  • 3.3.2 By application
  • 3.3.3 By patient type
  • 3.3.4 By distribution channel
• 3.4 COVID-19 impact analysis
• 3.5 Clinical trial analysis
• 3.6 Regulatory landscape
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
• 4.2 Company matrix analysis, 2022
• 4.3 Global Company market share analysis, 2022
• 4.4 Competitive positioning matrix, 2022
• 4.5 Strategic dashboard, 2022

Chapter 5 Nasal Spray Market Estimates and Forecast, By Type (USD Billion)

• 5.1 Key trends, by type
• 5.2 Steroids
• 5.3 Antihistamines
• 5.4 Decongestants
• 5.5 Saline solutions
• 5.6 Other types

Chapter 6 Nasal Spray Market Estimates and Forecast, By Application (USD Billion)

• 6.1 Key trends, by application
• 6.2 Sinusitis
• 6.3 Allergic rhinitis
• 6.4 Nasal polyps
• 6.5 Other applications

Chapter 7 Nasal Spray Market Estimates and Forecast, By Patient Type (USD Billion)

• 7.1 Key trends, by patient type
• 7.2 Adults
• 7.3 Pediatrics
• 7.4 Infants

Chapter 8 Nasal Spray Market Estimates and Forecast, By Distribution Channel (USD Billion)

• 8.1 Key trends, by distribution channel
• 8.2 Retail pharmacies
• 8.3 Hospital pharmacies
• 8.4 Online pharmacies

Chapter 9 Nasal Spray Market Estimates and Forecast, By Region (USD Billion)

• 9.1 Key trends, by region
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Switzerland
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East & Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of MEA

Chapter 10 Company Profiles

• 10.1 Bayer AG
• 10.2 Novartis AG
• 10.3 ADAPt Pharma, Inc.
• 10.4 Cipla Inc.
• 10.5 AbbVie Inc.
• 10.6 Aurena Laboratories
• 10.7 GlaxoSmithKline plc
• 10.8 Sun Pharmaceutical Industries Ltd.
• 10.9 Viatris Inc.
• 10.10 Leeford Healthcare Limited